Private company
Sofgen Pharma S.A.
Sofgen Pharma S.A. is a pharmaceutical preparations company.1
Last updated Oct 21, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue49¢$182.3M
- Other costs36¢$132.7M
- Interest11¢$42.5M
- Income tax4¢$16.3M
Out of $373.8M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2024
- Capital spending22¢$19.4M
- Kept or used elsewhere78¢$69.1M
Out of $88.4M of cash from operations.2
Financial statements
No quarterly figures reported.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $324.8M4 | $331.5M5 | $403.7M6 | $403.2M2 | $423.7M2 | $373.8M2 | |
| Cost of revenue | $173.7M6 | $168.1M2 | $185.8M2 | $182.3M2 | |||
| Gross profit | $182.5M4 | $191.3M5 | $230.1M6 | $235.1M2 | $238.0M2 | $191.5M2 | |
| Operating income | -$15.1M6 | $9.8M2 | $72.1M2 | -$54.0M2 | |||
| Interest | $85.6M6 | $25.8M2 | $40.9M2 | $42.5M2 | |||
| Income before tax | -$93.9M6 | $47.7M2 | $46.0M2 | -$84.6M2 | |||
| Income tax | $13.1M6 | $11.6M2 | $5.6M2 | -$16.3M2 | |||
| Net income | -$17.0M4 | -$10.4M5 | -$107.0M6 | $36.1M2 | $40.3M2 | -$68.3M2 | |
| Earnings per share | -$0.184 | -$0.115 | -$1.096 | $0.362 | $0.402 | -$0.682 | |
| Earnings per share (diluted) | -$0.115 | -$1.096 | $0.362 | $0.402 | -$0.682 | ||
| Shares (weighted, basic) | 98.1K shares6 | 101.1K shares2 | 101.0K shares2 | 100.3K shares2 | |||
| Shares (weighted, diluted) | 98.1K shares6 | 101.1K shares2 | 101.0K shares2 | 100.3K shares2 |
No quarterly figures reported.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $2.8M4 | $2.0M5 | $4.2M6 | $72.1M2 | $43.0M2 | $17.5M2 | $30.3M2 |
| Receivables | $100.0M6 | $106.4M6 | $124.9M2 | $78.3M2 | |||
| Inventory | $81.6M6 | $99.8M6 | $101.8M2 | $76.5M2 | |||
| Current assets | $284.9M6 | $279.3M6 | $275.6M2 | $216.7M2 | |||
| Property, plant and equipment | $71.4M6 | $70.6M6 | $91.0M2 | $93.7M2 | |||
| Goodwill | $6.8M6 | $5.8M2 | $06 | ||||
| Intangible assets | $30.1M6 | $32.2M6 | $42.9M2 | $30.3M2 | |||
| Total assets | $337.7M4 | $359.5M4 | $450.3M6 | $442.5M6 | $472.5M2 | $411.7M2 | |
| Accounts payable | $87.4M6 | $90.6M6 | $93.1M2 | $107.0M2 | |||
| Short-term debt | $224.3M6 | $257.9M6 | $268.4M2 | $226.6M2 | |||
| Current liabilities | $356.3M6 | $386.3M6 | $433.6M2 | $415.9M2 | |||
| Long-term debt | $29.0M6 | $29.2M6 | $31.1M2 | $41.4M2 | |||
| Long-term liabilities | $164.0M6 | $93.4M6 | $39.7M2 | $47.9M2 | |||
| Retained earnings | -$465.9M6 | -$432.5M6 | -$396.3M2 | -$471.4M2 | |||
| Shareholders’ equity | -$127.7M4 | -$243.9M5 | -$282.7M6 | -$70.0M2 | -$37.1M2 | -$736.0K2 | -$52.1M2 |
| Shares outstanding | 112.8M shares4 | 112.8M shares5 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash from operations | $68.3M4 | $70.9M5 | $35.5M6 | $15.6M2 | $107.6M2 | $88.4M2 | |
| Capital spending | $11.8M4 | $7.7M5 | $15.4M6 | $23.2M2 | $20.3M2 | $19.4M2 | |
| Free cash flow | $56.5M | $63.2M | $20.0M | -$7.6M | $87.3M | $69.1M | |
| Cash from investing | -$24.9M6 | -$32.4M2 | -$34.6M2 | -$26.8M2 | |||
| Dividends paid | $200.0K6 | $300.0K6 | |||||
| Share buybacks | $45.0M6 | $06 | $06 | ||||
| Cash from financing | $57.8M6 | -$12.8M2 | -$97.8M2 | -$50.4M2 |
Corporate structure
Sofgen Pharma S.A. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Sofgen Pharma S.A.
- Becaril S.A. Filed SCHEDULE 13D on Sofgen Pharma S.A., latest Apr 28, 2025
- Chemo Project, S.A. Filed SCHEDULE 13D on Sofgen Pharma S.A., latest Apr 25, 2025
- Flying Fish Ventures L.P. Filed SCHEDULE 13D on Sofgen Pharma S.A., latest Apr 22, 2025
- Saint Thomas Commercial S.A. Filed SCHEDULE 13D on Sofgen Pharma S.A., latest Apr 22, 2025
- Hoche Partners Pharma Holding S.A. Filed SCHEDULE 13D/A on Sofgen Pharma S.A., latest Apr 16, 2025 (15 filings since Oct 12, 2021)
- International Finance Corp Filed SC 13G on Sofgen Pharma S.A., latest Feb 14, 2022
- SOGNATORE TRUST Filed SC 13D on Sofgen Pharma S.A., latest Oct 12, 2021
- Sofgen Pharma S.A. N4
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Sofgen Pharma S.A. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | $93.7M2 Dec 31, 2024 | $91.0M2 Dec 31, 2023 | +3.0% |
| Operating-lease assets (leased space) | $40.3M2 Dec 31, 2024 | $46.7M2 Dec 31, 2023 | −13.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $30.3M2 Dec 31, 2024 | $17.5M2 Dec 31, 2023 | +73.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $06 Dec 31, 2023 | $5.8M2 Dec 31, 2022 | −100.0% |
| Intangible assets, net (excluding goodwill) | $30.3M2 Dec 31, 2024 | $42.9M2 Dec 31, 2023 | −29.3% |
Inventory
Leadership
Who has led Sofgen Pharma S.A., and when. Pick a name to see everywhere that person has worked.
Chief executive
- Chief executive officerAngelini Melissa Andreia Silva Mar 18, 2026 to now7
- Chief executive officerRuben Minski Oct 8, 2021 to Oct 8, 20218
Board members and other officers (11)
- Chief Commercial OfficerLuis Alberto Palacios Mar 30, 2026 to now9
- Board memberNicolas Alexandre Weinstein Mar 18, 2026 to now10
- Board memberCamacho Carlos Romero Mar 26, 2026 to now11
- Board memberClaro Manuel Jose Vial Mar 26, 2026 to now12
- Board memberAlberto Eguiguren Mar 30, 2026 to now13
- Board memberIragorri Carlos Garcia Mar 30, 2026 to now14
- Board memberJaramillo Daniel Augusto Bernal Mar 30, 2026 to now15
- Board memberMuniz Fernando Sebastian Moreira Mar 30, 2026 to now16
- Board memberJose Minski Oct 8, 2021 to Oct 8, 202117
- Board memberRuben Minski Oct 8, 2021 to Oct 8, 20218
- Board memberAlexandre Weinstein Manieu Oct 12, 2021 to now18
Former names
- Procaps Group, S.A.Jun 21, 2021 to Nov 19, 20253
Timeline
Filings
148 filings to the SEC since October 2021: 5 annual reports, 14 insider forms, 21 large holders, 108 other. The latest 20:
- Mar 30, 20263 EDGAR
- Mar 30, 20263 EDGAR
- Mar 30, 20263 EDGAR
- Mar 30, 20263 EDGAR
- Mar 30, 20263 EDGAR
- Mar 26, 20263 EDGAR
- Mar 26, 20263 EDGAR
- Mar 19, 20263 EDGAR
- Mar 18, 20263 EDGAR
- Mar 18, 20263 EDGAR
- Mar 16, 202615-12G EDGAR
- Mar 16, 202620-F ANNUAL REPORT EDGAR
- Dec 5, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Nov 19, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 3, 202520-F EDGAR
- Aug 1, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 14, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 13, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 1, 2025NT 20-F NOTIFICATION OF LATE FILING EDGAR
- Apr 28, 2025SCHEDULE 13D EDGAR
The 148 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- S.a. BecarilSCHEDULE 13D, 1 filing Apr 28, 202519
- Project S.a. ChemoSCHEDULE 13D, 1 filing Apr 25, 202520
- Flying Fish Ventures L.P.SCHEDULE 13D, 1 filing Apr 22, 202521
- Thomas Commercial S.a. SaintSCHEDULE 13D, 1 filing Apr 22, 202522
- Hoche Partners Pharma Holding S.A.SCHEDULE 13D/A, 15 filings Oct 12, 2021 to Apr 16, 202523
- International Finance CorpSC 13G, 1 filing Feb 14, 202224
- SOGNATORE TRUSTSC 13D, 1 filing Oct 12, 202125
SEC filer profile
How Sofgen Pharma S.A. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSofgen Pharma S.A.1
- CIK0001863362
- Filer statusNon-accelerated filer an emerging growth company; not a shell company26
- Incorporated inGrand Duchy of Luxembourg26
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address9 Rue De Bitbourg, Luxembourg, Luxembourg1
- Phone575-371-92801
- Shares outstanding112,824,184 Ordinary Shares shares; 23,375,000 Warrants shares as of Dec 31, 202426
- AuditorDeloitte & Touche S.A.S, Bogota, Colombia PCAOB ID 1183; no auditor attestation of internal control over financial reporting26
- On EDGAR sinceJun 21, 20211
- Filings173 in all: 6-K (83), 3 (14), SC 13D/A (13), 424B3 (12), 425 (10), 20-F (5), CORRESP (4), EFFECT (4)1
All 25 form types
SCHEDULE 13D (4), NT 20-F (3), UPLOAD (3), F-4/A (2), POS AM (2), RW (2), SC 13D (2), 15-12G (1), 20-F/A (1), 20FR12B (1), 25-NSE (1), 8-A12B (1), CERT (1), F-1 (1), F-4 (1), SC 13G (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (20-F) Mar 16, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary Shares, U.S.$0.01 nominal value per share | PROCF | |
| Warrants | PROCW |
From the cover page of the 20-F filed Mar 16, 2026 (Section 12(b) of the Exchange Act).26
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARCamacho Carlos Romero, Board member
- 12SEC EDGARClaro Manuel Jose Vial, Board member
- 13SEC EDGARAlberto Eguiguren, Board member
- 14SEC EDGARIragorri Carlos Garcia, Board member
- 15
- 16
- 17SEC EDGARJose Minski, Board member
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26